Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
21 Ιουλ 2021 · How is triple-negative breast cancer (TNBC) treated? Learn more about the treatment options for stages 1 to 4 of triple-negative breast cancer here.
Κυριότερες Ειδήσεις
26 Φεβ 2020 · High-risk early triple-negative breast cancer is frequently associated with early recurrence and high mortality. 1 Neoadjuvant chemotherapy is the preferred treatment approach. 2-4 In...
17 Αυγ 2022 · Following these results, the FDA approved Keytruda for the treatment of high-risk, early-stage triple-negative breast cancer in July 2021.
15 Φεβ 2023 · In this article, we review the current treatment landscape for early TNBC, from standard cytotoxic chemotherapy to recent data on immune checkpoint inhibitors, capecitabine, and olaparib. Keywords: triple-negative breast cancer, neoadjuvant chemotherapy, immune checkpoint inhibitor. 1. Introduction.
3 Ιαν 2024 · The immunotherapy approved for the treatment of triple-negative breast cancer is called pembrolizumab. It can be used with chemotherapy or other medicines before surgery and then continued alone after surgery to treat early stage, triple-negative breast cancer at high risk of recurrence.
11 Ιαν 2022 · Triple-negative breast cancer (TNBC) is associated with an increased risk of early recurrence and distant metastasis, as well as the development of therapeutic resistance and poor prognosis. TNBC is characterized by a wide range of genetic, immunophenotypic, morphological, and clinical features.
